Literature DB >> 9733217

Elevated plasma cholesteryl ester transfer in NIDDM: relationships with apolipoprotein B-containing lipoproteins and phospholipid transfer protein.

S Riemens1, A van Tol, W Sluiter, R Dullaart.   

Abstract

Lecithin:cholesteryl acyl transferase (LCAT) and cholesteryl ester transfer protein (CETP) are key factors in the esterification of cholesterol and the subsequent transfer of cholesteryl ester from high density lipoproteins (HDL) towards very low and low density lipoproteins (VLDL + LDL). Phospholipid transfer protein (PLTP), lipoprotein lipase (LPL) and hepatic lipase (HL) are involved in plasma phospholipid and triglyceride metabolism and also affect HDL. Equivocal changes in plasma cholesteryl ester transfer have been reported in non-insulin-dependent diabetes mellitus (NIDDM). In 16 NIDDM men with plasma triglycerides < or = 4.5 mmol/l and cholesterol < or = 8.0 mmol/l. plasma cholesteryl ester transfer (CET), cholesterol esterification rate, LCAT and PLTP activity levels were higher (P < 0.05 to P < 0.02) in conjunction with higher plasma triglycerides (P < 0.01) and lower HDL cholesterol and cholesteryl ester levels (P < 0.05) compared to 16 matched healthy men. Multiple stepwise regression analysis demonstrated that CET was positively related to VLDL + LDL cholesterol (P < 0.001), triglycerides (P = 0.001), PLTP activity (P = 0.007) and CETP activity (P = 0.008, multiple r = 0.94). NIDDM had no effect on CET, independently from these parameters. HDL cholesteryl ester was negatively related to CET (P= 0.017), HL activity (P = 0.033) and NIDDM (P = 0.047) and positively to LCAT activity levels (P = 0.034, multiple r = 0.68). It is concluded that the elevated CET in plasma from NIDDM patients is associated with higher plasma triglycerides and PLTP activity levels. Furthermore, our data suggest that in normo- and moderately dyslipidaemic subjects PLTP and CETP activity levels per se may influence the rate of cholesteryl ester transfer in plasma. Plasma cholesteryl ester transfer appears to be a determinant of HDL cholesteryl ester, but other factors are likely to contribute to lower HDL cholesteryl ester levels in NIDDM.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9733217     DOI: 10.1016/s0021-9150(98)00111-7

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  21 in total

Review 1.  Cardiovascular disease risk reduction by raising HDL cholesterol--current therapies and future opportunities.

Authors:  K Mahdy Ali; A Wonnerth; K Huber; J Wojta
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

2.  Elevated plasma phospholipid transfer protein activity is a determinant of carotid intima-media thickness in type 2 diabetes mellitus.

Authors:  R de Vries; G M Dallinga-Thie; A J Smit; B H R Wolffenbuttel; A van Tol; R P F Dullaart
Journal:  Diabetologia       Date:  2005-12-23       Impact factor: 10.122

Review 3.  Role of plasma phospholipid transfer protein in lipid and lipoprotein metabolism.

Authors:  John J Albers; Simona Vuletic; Marian C Cheung
Journal:  Biochim Biophys Acta       Date:  2011-06-28

Review 4.  Diabetes: mellitus or lipidus?

Authors:  E Shafrir; I Raz
Journal:  Diabetologia       Date:  2003-03-14       Impact factor: 10.122

5.  The impact of glycation on apolipoprotein A-I structure and its ability to activate lecithin:cholesterol acyltransferase.

Authors:  E Nobecourt; M J Davies; B E Brown; L K Curtiss; D J Bonnet; F Charlton; A S Januszewski; A J Jenkins; P J Barter; K-A Rye
Journal:  Diabetologia       Date:  2007-01-10       Impact factor: 10.122

Review 6.  Clinical significance of the physicochemical properties of LDL in type 2 diabetes.

Authors:  P G Scheffer; T Teerlink; R J Heine
Journal:  Diabetologia       Date:  2005-04-14       Impact factor: 10.122

Review 7.  Treatment of Dyslipidemias to Prevent Cardiovascular Disease in Patients with Type 2 Diabetes.

Authors:  Maryam Khavandi; Francisco Duarte; Henry N Ginsberg; Gissette Reyes-Soffer
Journal:  Curr Cardiol Rep       Date:  2017-01       Impact factor: 2.931

8.  Metabolic effects of fluvastatin extended release 80 mg and atorvastatin 20 mg in patients with type 2 diabetes mellitus and low serum high-density lipoprotein cholesterol levels: a 4-month, prospective, open-label, randomized, blinded-end point (probe) trial.

Authors:  Maurizio Bevilacqua; Barbara Guazzini; Velella Righini; Massimo Barrella; Rosanna Toscano; Enrica Chebat
Journal:  Curr Ther Res Clin Exp       Date:  2004-07

9.  Genetic and nongenetic sources of variation in phospholipid transfer protein activity.

Authors:  Gail P Jarvik; Ramakrishnan Rajagopalan; Elisabeth A Rosenthal; Gertrud Wolfbauer; Laura McKinstry; Aditya Vaze; John Brunzell; Arno G Motulsky; Deborah A Nickerson; Patrick J Heagerty; Ellen M Wijsman; John J Albers
Journal:  J Lipid Res       Date:  2009-11-02       Impact factor: 5.922

10.  Altered relationship of plasma triglycerides to HDL cholesterol in patients with HIV/HAART-associated dyslipidemia: further evidence for a unique form of metabolic syndrome in HIV patients.

Authors:  Catherine N Vu; Raul Ruiz-Esponda; Eric Yang; Evelyn Chang; Baiba Gillard; Henry J Pownall; Ron C Hoogeveen; Ivonne Coraza; Ashok Balasubramanyam
Journal:  Metabolism       Date:  2013-03-19       Impact factor: 8.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.